STOCK TITAN

Cosmos Health Reports Record Nine-Month Revenue of $53.6 Million, Up 18%; Q3 Gross Margin Up 465 Basis Points Sequentially; Total Debt Down 34% and Stockholders' Equity Up 21% Since Year-End

(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Cosmos Health (COSM) reported record revenue of $53.6 million for the first nine months of 2026. Revenue rose 17.6% year over year, but the nine-month net loss widened to $14.15 million from $9.00 million. Q3 revenue fell to $16.68 million from $17.11 million a year earlier. Q3 gross margin rose 465 basis points from Q2 to 12.6%, and Q3 net loss narrowed to $5.25 million from $5.35 million a year earlier.

Since year-end 2025, total debt fell 33.8% to $12.83 million and stockholders’ equity rose 21.2% to $22.33 million. Cosmos Health fully settled its $8.0 million ATW convertible note. Cana Laboratories’ contract manufacturing pipeline rose 31% since June to more than 32.7 million units. Cosmos Health completed a 1-for-20 reverse stock split effective November 13, 2026.

Loading...
Loading translation...
33 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 10 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major point$8.0 million ATW convertible note was fully settled with accrued interest approximately twelve months before its August 2027 maturity 56% of market cap
  • Moderate pointNine-month revenue reached a record $53.59 million, up 17.6% from $45.57 million a year earlier
  • Moderate pointStockholders’ equity rose 21.2% to $22.33 million at September 30 from $18.42 million at year-end 2025
  • Moderate pointQ3 gross margin rose 465 basis points to 12.6% from 7.96% in Q2
  • Moderate pointU.S. monthly subscription value reached $1.83 million as of October 31, approximately $22 million annualized
  • Moderate pointU.S. e-commerce sales reached $1.67 million in October
  • Moderate pointCana Laboratories’ manufacturing pipeline grew 31% since June to more than 32.7 million units under agreements extending up to ten years
  • Moderate pointCosmoFarm’s annualized revenue run rate exceeded $60 million based on Q2 revenue, approximately 4.3 times its revenue before Cosmos Health ownership
  • Moderate pointShare repurchases totaled 123,100 shares in Q3 for approximately $0.63 million 4.4% of market cap
  • Moderate pointAmazon UK sales rose 90% to $2.27 million over the trailing twelve months
23 minor points
  • Minor pointTotal debt fell 33.8% to $12.83 million at September 30 from $19.37 million at year-end 2025
  • Minor pointQ3 net loss narrowed to $5.25 million from $5.35 million a year earlier
  • Minor pointWorking capital rose to $2.34 million at September 30 from $0.12 million at year-end 2025
  • Minor pointTotal liabilities fell 18.2% to $38.49 million at September 30 from $47.05 million at year-end 2025
  • Minor pointConvertible notes fell 81% to $1.22 million since year-end 2025
  • Minor pointRelated derivative liability of $1.29 million was eliminated
  • Minor pointDebt-to-equity ratio fell to 0.57 times at September 30 from 1.05 times at year-end 2025
  • Minor pointLiabilities-to-equity ratio fell to 1.7 times at September 30 from 2.6 times at year-end 2025
  • Minor pointLiabilities-to-assets ratio fell to 63.3% at September 30 from 71.9% at year-end 2025
  • Minor pointQ3 interest expense fell 56.9% to $0.29 million from $0.67 million a year earlier
  • Minor pointQ3 salaries and wages fell 10.5% year over year
  • Minor pointU.S. direct-to-consumer subscriptions exceeded 12,500 active subscriptions as of October 31, 2026
  • Minor point. Forward-looking: it has not happened yet and may not happen.Cana’s manufacturing pipeline represents over $20 million in implied revenue and over $18 million in implied gross profit
  • Minor pointTarget Pharma agreements cover approximately 5.2 million units across two five-year manufacturing deals
  • Minor pointViofar agreement covers an additional 2.5 million manufacturing units over five years
  • Minor pointSaudi distribution agreement gives Innova Healthcare five years of exclusivity, with an initial order for 126,000 Sky Premium Life units
  • Minor point. Forward-looking: it has not happened yet and may not happen.Saudi distribution volumes are expected to exceed 5 million units over the initial agreement term
  • Minor pointCosmoFarm’s pharmacy customer base added more than 75 pharmacies during the first nine months of 2026
  • Minor point. Forward-looking: it has not happened yet and may not happen.CosmoFarm automation entered commissioning and could support over $120 million in annual revenue
  • Minor pointOceania e-commerce expansion reached Australia and New Zealand, with sales underway
  • Minor point. Forward-looking: it has not happened yet and may not happen.Pharma Cell partnership expansion in Albania is projected to generate annualized orders exceeding 54,000 units
  • Minor pointC-ScrubVet launched in the United Kingdom after successful testing and received its first orders
  • Minor point. Forward-looking: it has not happened yet and may not happen.CCX0722 hydrogel intellectual property is planned for tokenization under a structure Cosmos Health describes as non-dilutive

Negative

  • Major pointNine-month net loss widened to $14.15 million from $9.00 million a year earlier
  • Moderate pointNine-month operating loss widened to $7,683,275 from $5,297,179 a year earlier
  • Moderate pointNine-month gross profit fell to $4,996,836 from $5,816,231 a year earlier
  • Moderate pointQ3 operating loss widened to $2,573,489 from $1,818,715 a year earlier
  • Moderate pointNine-month adjusted EBITDA loss widened to $2,506,064 from $1,107,720 a year earlier
5 minor points
  • Minor pointNine-month operating expenses rose 14.1% year over year, below revenue growth of 17.6%
  • Minor pointQ3 revenue fell to $16.68 million from $17.11 million a year earlier, partly due to revenue reversals
  • Minor pointQ3 gross profit fell to $2,104,003 from $2,602,618 a year earlier
  • Minor pointQ3 operating expenses rose to $4,677,492 from $4,421,333 a year earlier
  • Minor pointQ3 adjusted EBITDA loss, a non-GAAP earnings measure, narrowed approximately 18% from Q2 to $0.93 million but widened from $185,014 a year earlier

News Explained

By September 30, 2026, the company had repurchased 255,600 shares for approximately $1.15 million under its $5.0 million authorization, leaving approximately $3.85 million available; further purchases are discretionary, and the program may be suspended or discontinued.

Key Figures

Nine-month revenue: $53.59 million, up 17.6% Q3 revenue: $16.68 million Gross margin: 12.6%, up 465 basis points +5 more
Nine-month revenue
$53.59 million, up 17.6%
Nine months ended September 30, 2026, versus 2025
Q3 revenue
$16.68 million
Q3 2026; broadly in line with $17.11 million in Q3 2025
Gross margin
12.6%, up 465 basis points
Q3 2026 versus Q2 2026
Adjusted EBITDA
Loss of $0.93 million
Q3 2026; improved approximately 18% sequentially from a loss of $1.13 million
Total debt
$12.83 million, down 33.8%
As of September 30, 2026, compared with year-end 2025
Stockholders' equity
$22.33 million, up 21.2%
As of September 30, 2026, compared with year-end 2025
Active subscriptions
More than 12,500
U.S. direct-to-consumer business as of October 31, 2026
Monthly subscription value
$1.83 million
U.S. direct-to-consumer business as of October 31, 2026

Previous Earnings Reports

2 past events · Latest: Oct 07
Same Type 2 events
  1. Oct 07

    Nine-month revenue

    24h Move
    +0.4%

    Preliminary nine-month revenue rose 19%; the reported period’s price reaction was positive.

  2. Nov 17

    Q3 results

    24h Move
    -3.1%

    Reported record Q3 revenue, gross profit and margin; the reported period’s price reaction was negative.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

adjusted ebitda, convertible notes, derivative liability, non-gaap
4 terms
adjusted ebitda financial
"Adjusted EBITDA improved approximately 18% sequentially"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
convertible notes financial
"net non-cash charges related primarily to the Company's convertible notes"
Convertible notes are a type of short-term loan that a company receives from investors, which can later be turned into company shares instead of being paid back in cash. They matter to investors because they offer a way to support a company early on while giving the potential to own a stake in its success if the company grows and later raises more funding.
derivative liability financial
"the related $1.29 million derivative liability was eliminated"
A derivative liability is an obligation a company owes because of a derivatives contract—such as an option, future, swap, or forward—that has moved against it and now has negative value. Think of it like a settled bet that turned into a bill: if market moves go the other way, the company may have to pay cash or deliver assets. Investors care because these liabilities can create sudden losses, add leverage or counterparty risk, and change a company’s true financial exposure beyond its everyday operations.
non-gaap financial
"These non-GAAP financial measures should not be considered in isolation"
Non-GAAP refers to financial measures that companies use to show their earnings or performance without including certain expenses or income that are often added back to give a different picture. It matters because it can make a company's results look better or more favorable, but it may also hide important costs, so investors need to look at both GAAP (official rules) and non-GAAP numbers to get a full understanding.
View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

CHICAGO, IL / ACCESS Newswire / November 18, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM),a diversified, vertically integrated global healthcare group, today reported financial results for the third quarter and nine months ended September 30, 2026, highlighted by record nine-month revenue, a strengthened balance sheet and a sequential improvement in gross margin and Adjusted EBITDA.

Third Quarter and Nine-Month 2026 Financial Highlights

Revenue

  • Nine-month revenue reached a record $53.59 million, up $8.03 million, or 17.6%, from $45.57 million in the first nine months of 2025, driven by strong momentum across core operating segments, including pharmaceutical distribution at CosmoFarm, which added more than 75 new pharmacies to its client portfolio during the period.
  • Third-quarter revenue was $16.68 million, broadly in line with $17.11 million in the third quarter of 2025, and was partially impacted by revenue reversals.

Sequential Improvement in Gross Margin and Adjusted EBITDA

  • Gross margin rebounded to 12.6% in Q3 2026, up 465 basis points from 7.96% in Q2 2026.
  • Adjusted EBITDA improved approximately 18% sequentially, to a loss of $0.93 million from a loss of $1.13 million in Q2 2026.

Operating Discipline

  • Nine-month total operating expenses grew 14.1%, below revenue growth of 17.6%.
  • Third-quarter salaries and wages declined 10.5% year-over-year, while the Company increased sales and marketing investment to support its brands.

Lower Interest Expense

  • Third-quarter interest expense fell 56.9% to $0.29 million, from $0.67 million in Q3 2025, as the Company reduced its debt during 2026.

Net Loss Driven by Non-Cash Charges

  • Third-quarter net loss narrowed to $5.25 million, from $5.35 million in Q3 2025.
  • Approximately $3.1 million, or 59%, of the Q3 net loss consisted of net non-cash charges related primarily to the Company's convertible notes, including non-cash interest expense and changes in fair value.

Balance Sheet Transformation

Cosmos Health continued to strengthen its capital structure in the third quarter, reducing total debt and total liabilities and increasing stockholders' equity in every quarter of 2026, while substantially improving working capital.

(in $ millions)
Dec 31, 2025 Mar 31, 2026 Jun 30, 2026 Sep 30, 2026 Change YTD
Total debt
19.37 17.81 15.82 12.83 -33.8%
Total liabilities
47.05 42.54 40.79 38.49 -18.2%
Stockholders' equity
18.42 19.83 20.67 22.33 +21.2%
Total debt-to-equity
1.05x 0.90x 0.77x 0.57x -45%
Total liabilities-to-equity
2.6x 2.1x 2.0x 1.7x -33%
  • Total assets were $60.82 million as of September 30, 2026. The asset base remains diversified, including a solid real estate and intellectual property portfolio.
  • Total liabilities decreased 18.2%, or $8.56 million, to $38.49 million from $47.05 million at year-end 2025, driven primarily by a 33.8% reduction in total debt to $12.83 million, which mainly reflected the full settlement of the $8.0 million ATW convertible note. Convertible notes fell 81% to $1.22 million, and the related $1.29 million derivative liability was eliminated.
  • Total stockholders' equity increased by $3.90 million, or 21.2%, to $22.33 million from $18.42 million at December 31, 2025, while the liabilities-to-assets ratio improved by approximately 860 basis points to 63.3% from 71.9%.
  • Working capital improved to $2.34 million, from $0.12 million at December 31, 2025.

Q3 2026 Business Highlights

U.S. Direct-to-Consumer

  • Launched the Company's U.S. subscription model in July 2026 and introduced an AI-enabled subscription platform across B2C and B2B channels.
  • Began scaling the U.S. direct-to-consumer business in mid-September 2026.

Commercial Expansion

  • CosmoFarm reached an annualized revenue run-rate of over $60 million, based on its record second-quarter 2026 revenue, approximately 4.3 times its revenue before Cosmos Health ownership, serving approximately 360 pharmacies daily within a network of more than 1,500.
  • Entered Saudi Arabia through an exclusive five-year distribution agreement with Innova Healthcare, with an initial purchase order of 126,000 Sky Premium Life® units and more than 5 million units expected over the initial term.
  • Expanded the Pharma Cell partnership in Albania, with annualized orders projected to exceed 54,000 units.
  • Signed an agreement with Libytec to commercialize DIABIT-IS X in Greece.

Contract Manufacturing: Record Pipeline

  • Cana Laboratories grew its contract manufacturing pipeline to a record of more than 32.7 million units across 11 therapeutic categories, up 31% since June 2026, under agreements extending up to ten years, representing over $20 million in implied revenue and over $18 million in implied gross profit, including:
  • Two five-year agreements with Target Pharma for approximately 5.2 million units of MUPIROCIN and TRETIN.
  • A five-year agreement with Viofar for an additional 2.5 million units.

Clinical Validation and New Categories

  • Launched C-ScrubVet in the United Kingdom, entering the $69 billion global animal health market following successful testing under EN 1656 and EN 1657, with first orders received.

R&D and Innovation

  • Announced plans to tokenize the CCX0722 hydrogel intellectual property in a non-dilutive structure, targeting the $562 billion weight-management market.

Capital Structure

  • Fully settled the $8.0 million ATW senior secured convertible note, including accrued interest, approximately twelve months ahead of its August 2027 maturity; no amounts remain outstanding under that note.
  • Repurchased 123,100 shares (2,462,000 pre-split) during the third quarter for approximately $0.63 million, bringing total repurchases under the Company's $5.0 million share repurchase program to 255,600 shares (5,112,000 pre-split) for approximately $1.15 million.

Subsequent to Quarter-End

  • U.S. direct-to-consumer business reached more than 12,500 active subscriptions and $1.83 million in monthly subscription value as of October 31, 2026, approximately $22 million annualized, with October U.S. e-commerce sales of $1.67 million.
  • Expanded the e-commerce and subscription business to Australia, New Zealand and the broader Oceania region, with sales underway.
  • Brands now sold in more than 40 countries across Europe, the Middle East, North America and Asia.
  • Amazon UK sales grew 90% to $2.27 million over the trailing twelve months.
  • CosmoFarm began commissioning new automated order-processing and vehicle-loading infrastructure, building capacity that could support over $120 million in annual revenue.
  • Effected a 1-for-20 reverse stock split of its common stock, effective November 13, 2026.
  • Noble Capital Markets initiated equity research coverage of Cosmos Health with an Outperform rating.

Share Repurchase Program

On June 26, 2026, the Company's Board of Directors authorized the repurchase of up to $5.0 million of the Company's common stock. During the third quarter of 2026, the Company repurchased 123,100 shares (2,462,000 pre-split) for approximately $0.63 million, bringing total repurchases under the program as of September 30, 2026 to 255,600 shares (5,112,000 pre-split) for approximately $1.15 million, with approximately $3.85 million remaining available.

The Company may make further open-market repurchases from time to time, in accordance with applicable securities laws. The timing and amount of any repurchases will depend on market conditions and other factors, and the program may be suspended or discontinued at any time.

The Company will continue to evaluate capital allocation priorities, balancing strategic growth investments, liquidity requirements, debt reduction and potential share repurchases in accordance with market conditions and the Company's financial position.

CEO Commentary

Greg Siokas, CEO of Cosmos Health, stated: "We are pleased with our progress this year. We delivered record nine-month revenue of $53.6 million, up 18%, driven by strong momentum across our core segments. And we have strengthened the balance sheet: since January we have cut total debt by a third, reduced total liabilities by 18%, grown stockholders' equity by more than 20%, cut convertible notes by more than 80% and fully settled the ATW note approximately a year ahead of maturity.

"The third quarter also showed sequential improvement: gross margin rebounded by 465 basis points from the second quarter, Adjusted EBITDA improved by approximately 18% sequentially, and interest expense fell by more than half year-over-year.

"What excites me most is what we are building in the United States. In roughly six weeks of scaling, our direct-to-consumer business grew to more than 12,500 active subscriptions and $1.83 million in monthly subscription value, approximately $22 million annualized. Together with a record contract manufacturing pipeline of more than 32.7 million units, entry into markets including Saudi Arabia and Oceania and new automation at CosmoFarm, we have entered the fourth quarter with strong momentum. Looking ahead, we believe Cosmos Health is well positioned for continued growth, and that the progress achieved in 2026 has established a stronger foundation for the next phase of Cosmos Health's development."

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

Three Months Ended September 30, Nine months ended September 30,
2026 2025 2026 2025
(in $)
GAAP FIGURES
REVENUE
16,679,476 17,110,425 53,593,744 45,568,655
GROSS PROFIT
2,104,003 2,602,618 4,996,836 5,816,231
TOTAL OPERATING EXPENSES
4,677,492 4,421,333 12,680,111 11,113,410
GAIN (LOSS) FROM OPERATIONS
-2,573,489 -1,818,715 -7,683,275 -5,297,179
NET LOSS
-5,253,880 -5,352,890 -14,145,825 -8,999,055
NON-GAAP FIGURES
ADJUSTED REVENUE
16,705,469 17,110,425 54,422,265 45,568,655
ADJUSTED GROSS PROFIT
2,129,996 2,602,618 5,825,357 5,816,231
ADJUSTED EBITDA
-931,591 -185,014 -2,506,064 -1,107,720
ADJUSTED NET INCOME (LOSS)
-1,219,713 -854,164 -3,819,779 -2,352,791

(*) See "Definitions of Non-GAAP Measures" and "Reconciliation of Non-GAAP Measures" sections herein for an explanation and reconciliations of non-GAAP measures used throughout this release.

Definitions of Non-GAAP Measures

We collect and analyze operating and financial data to evaluate the health of our business and assess our performance. In addition to Revenue, Gross Profit, Income (Loss) from Operations and Net Income (Loss) under GAAP, we use: Adjusted Revenue, Adjusted Gross Profit, EBITDA, Adjusted EBITDA, and Adjusted Net Income (Loss). We have included these non-GAAP financial measures because they are key measures used by our management to evaluate our operating performance. Accordingly, we believe that these non-GAAP financial measures provide useful information to investors and others in understanding and evaluating our operating results in the same manner as our management team and Board of Directors. Therefore, these non-GAAP financial measures are presented here. Our calculation of these non-GAAP financial measures may differ from similarly titled non-GAAP measures, if any, reported by our peer companies. These non-GAAP financial measures should not be considered in isolation from, or as substitutes for, financial information prepared in accordance with GAAP.

Adjusted Revenue

We define Adjusted Revenue as GAAP Revenue adjusted to include revenues subject to revenue recognition timing adjustments. Adjusted Revenue is supplemental in nature and is not meant as a substitute for Revenue prepared in accordance with GAAP.

Adjusted Gross Profit

We define Adjusted Gross Profit as GAAP Gross Profit adjusted for the same revenue recognition timing adjustments described under Adjusted Revenue above. Adjusted Gross Profit is supplemental in nature and is not meant as a substitute for Gross Profit prepared in accordance with GAAP.

Adjusted EBITDA

We define Adjusted EBITDA as Income (Loss) before Income Taxes, excluding (i) depreciation and amortization expense, (ii) interest income (expense), net, (iii) non-cash interest expense and change in fair value of convertible notes, (iv) stock-based compensation expense, (v) non-recurring and extraordinary items, (vi) other income (expense), net, (vii) gain (loss) on equity investments, net, (viii) change in fair value of derivative liability, (ix) gain (loss) on digital assets, (x) foreign currency transaction, net, and (xi) sales discount reversals.

We have included Adjusted EBITDA because it is a key measure used by our management team to evaluate our operating performance, generate future operating plans, and make strategic decisions. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management team and Board of Directors. In addition, it provides a useful measure for period-to-period comparisons of our business, as it removes the effect of certain non-cash expenses and non-recurring and extraordinary items.

For investors to better evaluate the Company's performance and compare results across reporting periods, Cosmos Health provides a reconciliation of GAAP to non-GAAP financial measures. These adjustments exclude certain non-cash and non-recurring items, including stock-based compensation, non-cash interest expense, changes in the fair value of derivatives and convertible notes, gains or losses on digital assets, foreign currency transactions, sales discount reversals, and other non-operating or non-recurring items, as applicable and as further described above.

The presentation of the Company's non-GAAP financial measures is not meant to be considered in isolation or as a substitute for the Company's financial results prepared in accordance with GAAP, and the Company's non-GAAP measures may be different from non-GAAP measures used by other companies. Adjusted EBITDA has limitations as a financial measure, should be considered as supplemental in nature, and is not meant as a substitute for the related financial information prepared in accordance with GAAP.

Adjusted Net Income (Loss)

We define Adjusted Net Income (Loss) as Adjusted EBITDA (see above) adding provision for income taxes and deducting interest expense.

Adjusted Net Income (Loss) has limitations as a financial measure, should be considered as supplemental in nature, and is not meant as a substitute for the related financial information prepared in accordance with GAAP.

Reconciliation of Non-GAAP Measures

Adjusted Revenue, Adjusted Gross Profit, Adjusted EBITDA & Adjusted Net Income (Loss)

The following table presents reconciliations of Adjusted Revenue, Adjusted Gross Profit, Adjusted EBITDA and Adjusted Net Income (Loss) to the most directly comparable GAAP financial measures for each of the periods indicated.

Three Months Ended September 30, Nine months ended September 30,
2026 2025 2026 2025
(in $)
REVENUE
16,679,476 17,110,425 53,593,744 45,568,655
Sales discount reversal
25,993 - 828,521 -
ADJUSTED REVENUE
16,705,469 17,110,425 54,422,265 45,568,655
GROSS PROFIT
2,104,003 2,602,618 4,996,836 5,816,231
Sales discount reversal
25,993 - 828,521 -
ADJUSTED GROSS PROFIT
2,129,996 2,602,618 5,825,357 5,816,231
INCOME (LOSS) BEFORE INCOME TAXES
-5,253,880 -5,352,890 -14,145,825 -8,999,055
Adjustments (add back):
Depreciation and amortization expense
343,087 377,911 1,040,447 1,052,212
Interest (income) / expense, net
288,122 669,150 1,313,715 1,245,071
Non-cash interest expense
2,940,463 201,447 3,732,226 364,550
EBITDA
-1,682,208 -4,104,382 -8,059,437 -6,337,222
Sales discount reversal
25,993 - 828,521 -
Non-recurring and extraordinary items
367,743 584,490 1,216,111 1,109,203
Stock based compensation
862,220 570,602 1,956,864 1,730,233
Other (income) / expense, net
115,324 5,577 -363,717 115,904
(Gain) / loss on equity investments, net
-5,377 -2,998 2,225 -8,779
Non-cash interest expense / Change in fair value of convertible notes
657,563 2,178,039 2,802,457 2,317,631
Change in fair value of derivative liability
-482,883 311,778 -1,292,198 311,778
Gain/(Loss) on digital assets
-783,018 -57 63,566 -57
Foreign currency transaction, net
-6,949 271,937 339,544 -346,411
ADJUSTED EBITDA
-931,591 -185,014 -2,506,064 -1,107,720
Interest income / (expense), net
-288,122 -669,150 -1,313,715 -1,245,071
ADJUSTED NET INCOME
-1,219,713 -854,164 -3,819,779 -2,352,791

CONDENSED CONSOLIDATED BALANCE SHEET DATA


September 30,
2026
June 30,
2026
March 31,
2026
(in $)
(Unaudited) (Unaudited) (Unaudited)
ASSETS
Cash & cash equivalents
1,091,385 2,445,168 2,158,921
Inventory
7,192,533 4,518,560 5,650,458
Accounts receivable, prepaid expenses and other current assets
28,455,111 29,217,388 28,594,752
Property and equipment, net
10,034,117 10,140,150 10,280,203
Goodwill and intangible assets, net
6,736,815 6,965,934 7,225,011
Loans receivable
3,371,528 3,472,916 3,605,388
Other noncurrent assets
3,934,685 4,701,838 4,854,278
TOTAL ASSETS
60,816,174 61,461,954 62,369,011
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable and accrued expenses
16,167,249 15,297,625 15,689,061
Other current liabilities
7,103,687 6,760,621 6,701,051
Lines of credit
8,653,475 8,745,807 7,856,208
Notes payable
4,176,506 7,075,633 9,954,812
Other non-current and finance/lease liabilities
2,387,624 2,907,785 2,341,520
Stockholders' and mezzanine equity
22,327,633 20,674,484 19,826,359
TOTAL LIABILITIES AND STOCKHOLDERS'/MEZZANINE EQUITY
60,816,174 61,461,954 62,369,011

About Cosmos Health Inc.

Cosmos Health Inc. (NASDAQ: COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.

Forward-Looking Statements

With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to: the Company's ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company's business, operations, and the economy in general; the Company's ability to successfully develop and commercialize its proprietary products and technologies; the timing, execution, regulatory clearance, valuation, structuring, and completion of any potential asset-backed or tokenized financing program; the legal, regulatory, and technological risks associated with digital assets and blockchain-based financial structures; the conversion of contract manufacturing pipeline volumes into production and revenue, including the timing, volume and terms of orders placed under multi-year agreements; the realization of anticipated gross margins; the timing, cost and completion of planned capital investments; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties - many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us - as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC's website (www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.

Investor Relations Contact:

BDG Communications
cosm@bdgcommunications.com

SOURCE: Cosmos Health Inc.



View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How did Cosmos Health’s Q3 2026 gross margin and net loss change?

Cosmos Health’s Q3 gross margin rose 465 basis points from Q2 to 12.6%, and its Q3 net loss narrowed to $5.25 million from $5.35 million a year earlier.

When did the Cosmos Health reverse stock split take effect, and what was the ratio?

Cosmos Health’s 1-for-20 reverse split of its common stock took effect on November 13, 2026.

How much of Cosmos Health’s Q3 2026 net loss came from non-cash charges?

Net non-cash charges accounted for approximately $3.1 million, or 59%, of the Q3 net loss. They were primarily related to convertible notes and included non-cash interest expense and changes in fair value.

How much was left in Cosmos Health’s share buyback program at September 30, 2026?

Cosmos Health had approximately $3.85 million remaining under its share repurchase program as of September 30. By then, it had repurchased 255,600 shares (5,112,000 pre-split) for approximately $1.15 million under the program.

Keep reading